SELLAS Life Sciences Group (DB:RXK3) - Hisse Senedi Fiyatı, Haberler ve Analizler

RXK3 Stoklara Genel Bakış

Amerika Birleşik Devletleri'nde çeşitli kanser endikasyonları için yeni kanser immünoterapilerinin geliştirilmesine odaklanan geç aşama bir klinik biyofarmasötik şirketi olan SELLAS Life Sciences Group, Inc. Daha fazla detay

RXK3 temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	0/6

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

1 yıldan az nakit akışı var

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

+ 2 daha fazla risk

SELLAS Life Sciences Group, Inc. Rakipler

4SC

DB:VSC

€51.9m

Heidelberg Pharma

XTRA:HPHA

€106.7m

Medigene

XTRA:MDG1

€20.6m

2invest

XTRA:2INV

€63.2m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti SELLAS Life Sciences Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.12
52 Haftanın En Yüksek Seviyesi	US$1.64
52 Haftanın En Düşük Seviyesi	US$0.45
Beta	2.4
11 Aylık Değişim	11.58%
3 Aylık Değişim	-5.41%
1 Yıllık Değişim	23.81%
33 Yıllık Değişim	-81.15%
5 Yıllık Değişim	-73.76%
Halka arzdan bu yana değişim	-99.60%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	RXK3	DE Biotechs	DE Pazar
7D	-6.1%	-0.2%	0.8%
1Y	23.8%	-16.9%	9.1%

Getiri vs. Endüstri: RXK3 geçen yıl % -16.9 oranında getiri sağlayan German Biotechs sektörünü aştı.

Getiri vs Piyasa: RXK3 geçen yıl % 9.1 oranında getiri sağlayan German Piyasasını aştı.

Fiyat Oynaklığı

Is RXK3's price volatile compared to industry and market?
RXK3 volatility
RXK3 Average Weekly Movement	9.6%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: RXK3 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: RXK3 'nin haftalık oynaklığı son bir yılda 17% dan 10% a düştü, ancak hâlâ German hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	16	Angelos Stergiou	www.sellaslifesciences.com

Geç aşama bir klinik biyofarmasötik şirketi olan SELLAS Life Sciences Group, Inc. Amerika Birleşik Devletleri'nde çeşitli kanser endikasyonları için yeni kanser immünoterapilerinin geliştirilmesine odaklanmaktadır. Şirketin öncü ürün adayı, akut miyeloid lösemi tedavisi için Faz 3 klinik çalışmalarında ve yumurtalık kanseri tedavisi için Faz 1/2 klinik çalışmalarında olan Wilms tümörü 1'i hedef alan bir kanser immünoterapötik ajanı olan galinpepimut-S'dir (GPS). Merck & Co., Inc. ile hematolojik maligniteler ve solid tümörler dahil olmak üzere beş kanser endikasyonundaki hastaları kapsayan bir Faz 1/2 klinik çalışmasında PD1 engelleyici pembrolizumab ile birlikte uygulandığında GPS'i değerlendirmek için stratejik bir işbirliği vardır; ve şu anda Faz 1 klinik çalışmalarında olan oldukça seçici küçük moleküllü bir CDK9 inhibitörü olan GFH009'un geliştirilmesi ve ticarileştirilmesi için GenFleet Therapeutics (Shanghai), Inc. SELLAS Life Sciences Group, Inc. şirketinin merkezi New York, New York'ta bulunmaktadır.

SELLAS Life Sciences Group, Inc. Temel Bilgiler Özeti

SELLAS Life Sciences Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
RXK3 temel i̇stati̇sti̇kler
Piyasa değeri	€78.56m
Kazançlar(TTM)	-€30.80m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-2.6x

F/K Oranı

RXK3 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
RXK3 gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$32.28m
Kazançlar	-US$32.28m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.46
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

RXK3 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

RXK3 Stoklara Genel Bakış

Risk Analizi

SELLAS Life Sciences Group, Inc. Rakipler

DB:VSC

€51.9m

XTRA:HPHA

€106.7m

XTRA:MDG1

€20.6m

XTRA:2INV

€63.2m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

Recent updates

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met

New major risk - Financial position

SELLAS Life Sciences Reports Positive Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Group, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial of GFH009 in Acute Myeloid Leukemia

Sellas Life Sciences Group, Inc. Announces Positive Topline Data from Gfh009 Phase 1 Dose-Escalation Trial in Acute Myeloid Leukemia Cohort Supporting Advancement to Phase 2 Clinical Study

Full year 2022 earnings released: US$2.13 loss per share (vs US$1.34 loss in FY 2021)

SELLAS Life Sciences Group, Inc. Appoints John T. Burns as Chief Financial Officer

SELLAS Life Sciences Group, Inc. Appoints Andrew Elnatan as Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality

SELLAS Life Sciences Group, Inc. Announces Positive Phase 1 Data with CDK9 Inhibitor GFH009 Monotherapy in Patients with Relapsed/Refractory Hematologic Malignancies

SELLAS Life Sciences Group, Inc. ’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vivo Study

Third quarter 2022 earnings released: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Announces Update on Phase 3 Regal Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces Confirmatory Top-Line Data Showing Survival and Clinical Benefits Based on the Final Analysis of the Phase 1/2 Clinical Trial of Galinpepimut-S in Combination with Keytruda® (Pembrolizumab) in Patients with Wt1+ Platinum-Resistant Advanced Ovarian Cancer

SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S

Insufficient new directors

SELLAS Life Sciences Group Announces Results from New Preclinical in Vitro Study for its Highly Selective CDK9 Inhibitor, GFH009

SELLAS Life Sciences Group, Inc. Announces Election of Katherine Bach Kalin to Its Board of Directors

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.30 loss in 2Q 2021)

SELLAS Life Sciences Group, Inc. Announces Results from Preclinical in Vitro Studies for CDK9 inhibitor, GFH009

SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009

SELLAS Life Sciences Group, Inc. Provides Clinical Update for GFH009 Ongoing Phase 1 Clinical Trial

SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo

SELLAS Life Sciences Group, Inc. Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer

First quarter 2022 earnings released: US$1.05 loss per share (vs US$0.16 loss in 1Q 2021)

Insufficient new directors

SELLAS Life Sciences Group, Inc. Launches Expand Access Program for Galinpepimut-S